Michelle Gill - Artificial Intelligence Driven Drug Discovery
Artificial Intelligence Driven Drug Discovery
By Michelle Gill
Abstract:
At BenevolentAI, we use machine learning to facilitate drug discovery. This talk will introduce the drug discovery process and explain how machine learning maps to these stages. We will then cover challenges specifically related to using machine learning for scientific discovery, and conclude with a specific application of reinforcement learning to generate novel compounds in silico.
Bio:
Michelle Gill is a Senior Data Scientist at BenevolentAI, an AI healthcare company with capabilities from early discovery to late stage clinical development. At BenevolentAI, she utilizes data science and machine learning to facilitate both the target identification and lead optimization stages of drug discovery. Previously, Michelle was a deep learning consultant within NVIDIA’s Professional Services Group where she assisted clients in the pharmaceutical and materials science domains develop proof of concept deep learning pipelines. As a scientist at the National Cancer Institute, she developed software utilizing machine learning and compressed sensing algorithms. She holds a PhD in Molecular Biophysics and Biochemistry from Yale University and completed a postdoctoral research fellowship at Columbia University Medical School, where she developed and applied biophysical methods to study the function of cancer-associated enzymes. Michelle's scientific and machine learning work has been published in peer reviewed journals and covered by the press.
Twitter: @modernscientist
Presented at the 2019 New York Conference (May 10th, 2019)
Видео Michelle Gill - Artificial Intelligence Driven Drug Discovery канала Lander Analytics
By Michelle Gill
Abstract:
At BenevolentAI, we use machine learning to facilitate drug discovery. This talk will introduce the drug discovery process and explain how machine learning maps to these stages. We will then cover challenges specifically related to using machine learning for scientific discovery, and conclude with a specific application of reinforcement learning to generate novel compounds in silico.
Bio:
Michelle Gill is a Senior Data Scientist at BenevolentAI, an AI healthcare company with capabilities from early discovery to late stage clinical development. At BenevolentAI, she utilizes data science and machine learning to facilitate both the target identification and lead optimization stages of drug discovery. Previously, Michelle was a deep learning consultant within NVIDIA’s Professional Services Group where she assisted clients in the pharmaceutical and materials science domains develop proof of concept deep learning pipelines. As a scientist at the National Cancer Institute, she developed software utilizing machine learning and compressed sensing algorithms. She holds a PhD in Molecular Biophysics and Biochemistry from Yale University and completed a postdoctoral research fellowship at Columbia University Medical School, where she developed and applied biophysical methods to study the function of cancer-associated enzymes. Michelle's scientific and machine learning work has been published in peer reviewed journals and covered by the press.
Twitter: @modernscientist
Presented at the 2019 New York Conference (May 10th, 2019)
Видео Michelle Gill - Artificial Intelligence Driven Drug Discovery канала Lander Analytics
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Machine learning in drug discovery: what can go wrong? — Vikram Sundar](https://i.ytimg.com/vi/m1kTpZ2Ly5g/default.jpg)
![Artificial Intelligence and Machine Learning: Innovations in Clinical Trial Data Automation](https://i.ytimg.com/vi/II_iRYPyqaE/default.jpg)
![Artificial intelligence and algorithms: pros and cons | DW Documentary (AI documentary)](https://i.ytimg.com/vi/s0dMTAQM4cw/default.jpg)
![Alan Turing and the Birth of Artificial Intelligence - Dermot Turing, at USI](https://i.ytimg.com/vi/PRK1eUqqIgg/default.jpg)
![AI for Drug Design - Lecture 16 - Deep Learning in the Life Sciences (Spring 2021)](https://i.ytimg.com/vi/AHVJv5RNqKs/default.jpg)
![Drug Discovery/Medicinal Chemistry at UCLA: Xtandi and Others](https://i.ytimg.com/vi/x0UqTZcuFdE/default.jpg)
![Drug Discovery, Biotech, and AI with Alex Zhavoronkov, CEO, Insilico Medicine (CXOTalk #327)](https://i.ytimg.com/vi/JaBO1pISZn8/default.jpg)
![Schrödinger](https://i.ytimg.com/vi/sWV3l90vp54/default.jpg)
![Drug discovery and development process](https://i.ytimg.com/vi/3Gl0gAcW8rw/default.jpg)
![The incredible inventions of intuitive AI | Maurice Conti](https://i.ytimg.com/vi/aR5N2Jl8k14/default.jpg)
![Jim Wells and Michelle Arkin(UCSF) Part 1: Introduction to Drug Discovery](https://i.ytimg.com/vi/KQKppAAR3ME/default.jpg)
![AWS re:Invent 2019: Enhancing clinical trials with machine learning (LFS203)](https://i.ytimg.com/vi/1AJDB69WivM/default.jpg)
![From idea to medicine | Drug development at Roche](https://i.ytimg.com/vi/attNofZ7AnY/default.jpg)
![Machine Learning: A New Approach to Drug Discovery | Daphne Koller | WiDS 2020](https://i.ytimg.com/vi/V6bSlPNwrKo/default.jpg)
![Artificial Intelligence Colloquium: Accelerating Chemistry with AI](https://i.ytimg.com/vi/dwgwk2DP6EA/default.jpg)
![Machine learning for drug design](https://i.ytimg.com/vi/Kw75RsNuQcE/default.jpg)
![Target Validation / Biochemical and Cellular Assay Development](https://i.ytimg.com/vi/JjbOBbr4q0s/default.jpg)
![MIT Quest for Intelligence Launch: AI-Driven Drug Discovery](https://i.ytimg.com/vi/aqMRrRS_0JY/default.jpg)
![From the Human Genome Project to Precision Medicine: A Journey to Advance Human Health - Eric Green](https://i.ytimg.com/vi/C4dT3JWXCDI/default.jpg)
![Using AI to Accelerate Drug Discovery // Jerome Pesenti, BenevolentAI (FirstMark's Data Driven)](https://i.ytimg.com/vi/u29_gdRbHq0/default.jpg)